Gubra A/S
GUBRA
ISIN DK0062266474 / Valor 125706804
Gubra A/S
UMushroom community rating:
About company
Gubra A/S is a specialized company focusing on high-end preclinical contract research and peptide-based drug discovery, particularly within the realms of metabolic and fibrotic diseases. Utilizing advanced models and technologies, Gubra provides rapid and high-quality data through its comprehensive services. The company’s light-sheet microscopy platform enables 3D imaging of organs in mice and rats, while its automated imaging pipeline and AI-driven image analysis ensure precise drug distribution mapping and histological quantification. Gubra offers a range of histology services, including core histology, multiplex immunohistochemistry, RNAScope®, and unbiased stereology analysis. Additionally, the company provides specialized models for cardiovascular diseases, such as hypertension-induced heart failure and atherosclerosis, complemented by state-of-the-art echocardiography and quantitative whole-heart 3D histology. Gubra also excels in peptide drug discovery, leveraging its AI-driven streaMLine platform to develop clinical-ready drug candidates with robust intellectual property protection. The company’s expertise spans linear, cyclic, disulfide-rich peptides, and peptide drug-conjugates, facilitating the transition from target identification to in vivo target validation.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (14.10.2025):
Gubra A/S has reported its interim results for the first half of 2025, achieving record-high group revenue and earnings. The company also reported a record quarter, although it has revised its outlook for the CRO business.
Record Revenue and Earnings
The group achieved a record high in both revenue and earnings during the first half of 2025.
Record Quarter
Gubra A/S reported a record quarter, demonstrating strong performance across its operations.
Revised CRO Business Outlook
The company has revised its outlook for the Contract Research Organization (CRO) business, reflecting changes in market conditions.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1152 M
Market cap (USD)
21,099
Daily traded volume (Shares)
634 / 618
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
